Medincell Stock Drops 3.5% and Hits Resistance at €28.52
The Montpellier-based biotech faces a significant halt in late morning trading, after several rebound sessions. The stock plunges to the lower end of the broader index, going against the grain of a well-oriented Parisian market. This movement comes after a particularly dynamic week for the stock.
A Sharp Drop After a Week of Nearly 13% Rebound
Medincell's stock loses 3.48% to €28.26, down from €29.28 the previous day. The stock is among the largest declines in the SBF 120, while the broader index is up by 0.71% during the session. This movement contrasts with the recent dynamics: the stock still shows nearly a 13% increase over the week and +21.5% over three months. Over one year, the performance remains very favorable, at +71.6%.
The decline today extends a phase of volatility that began in mid-June, when the publication of annual accounts had led to a 13.5% drop. Since then, the stock has alternated between rebounds and setbacks, before accelerating sharply upwards at the end of last week, culminating in a 5% jump on Tuesday that had brought it to challenge the resistance at €28.52. This level, now broken downwards during the session after being touched the previous day, becomes a technical reference point again.
A Lower Support at €24.08 and a Calendar Focused on Olanzapine LAI
The price remains well above its three moving averages: the MM20 (€26.65) is exceeded by 6%, the MM50 (€26.38) and the MM200 (€26.27) are surpassed by about 7%. The RSI at 62 indicates a still buying dynamic despite today's air pocket, without a signal of overheating. The next identified support is at €24.08, nearly 15% below the current price.
On the fundamentals side, during the publication of the annual results for 2025/2026 on June 16, 2026, the company highlighted two drivers for the current fiscal year: the continued growth of Uzedy royalties and the commercial launch of Olanzapine LAI, expected in the fourth quarter of 2026. Uzedy royalties had jumped 42% to €9.3 million in the past fiscal year, while the net loss had widened to €31.3 million. The ramp-up in operational expenses to support this expansion remains a point to be monitored by analysts.
